Blood vessels won't grow properly in tissues that are too stiff or too loose. (Project Gutenberg/Wikimedia Commons)
By Tom Ulrich
LeMaitre Vascular beats Wall Street 's expectations with a 2nd consecutive quarter of double-digit sales growth as profits soar 120%, sending shares up yesterday on Wall Street.
Profits soared 120% for LeMaitre Vascular (NSDQ:LMAT) during the 1st quarter on its 2nd consecutive quarter of double-digit sales growth, as the medical device company beat Wall Street's earnings expectations by a penny.
AtheroMed, which is developing an atherectomy device to treat peripheral artery disease, reports a $6 million funding round.
AtheroMed said it's raised a $6 million equity round, taking its total funding raise since 2009 to $20 million, according to regulatory filings.
The Menlo Park, Calif.-based medical device company is developing an atherectomy device for treating peripheral artery disease, according to its website.
AtheroMed is still flying under the radar, to judge by the 1-page website, which provides only an email link to contact the company.
Privately-held medical device company Mercator MedSystems touts regulatory wins in the EU for a pair of micro-infusion catheters for trating peripheral artery disease.
Mercator MedSystems touted European regulatory approvals for a pair of micro-infusion catheters for the treatment of peripheral artery disease.
The San Leandro, Calif.-based medical device company received CE Mark approval in the European Union to market its Cricket and Bullfrog catheters, which are designed to inject therapeutic agents safely through blood vessel walls into deep tissues. The pair of products already have FDA clearance for the U.S. market.
Medical device company Covidien releases 2-year study results combating a government-funded study that questioned the benefit of medical device intervention in stroke patient's future independence.
Medical device maker Covidien (NYSE:COV) touted 2-year study results demonstrating the safety and efficacy of its Solitaire FR revascularization system, combating another recently published study that questioned whether devices like Solitaire in provide long-term benefits to stroke patients.
Angioslide raises $6.3M Series C funding round from TriVentures and its return investors Viola Partners,Agate and XT Investments to expand its market in the U.S.
Israel-based Angioslide closed a $6.3 million Series C financing round led by TriVentures, a venture capital fund specializing in medical device technology investments, aimed at expanding its technology in the U.S.
Also participating in the round was return investor's Viola Partners, Agate and XT Investments, according to the company.
Medical device company Covidien expects to put at least $50 million toward R&D to progress drug-coated balloon technologies its about to acquire from CV Ingenuity.
Massachusetts medical device company Covidien (NYSE:COV) signed a definitive agreement to acquire drug-coated balloon maker CV Ingenuity, planning to put millions toward R&D over the next 2 years.